A credible path to breakeven is emerging alongside accelerating AI-driven biology demand. Upside depends on attaching regulated OEM and workflow software to reduce churn and lift the quality of revenues by 2031.

As AI makes biological design cheap and fast, the bottleneck shifts to trustworthy, high-throughput “DNA writing” and validated genomics workflows; Twist can compound by scaling core synthesis + NGS consumables while attaching regulated OEM, workflow software, and provenance features that turn compliance and reliability into a higher-quality multiple by 2031.

AI accelerates iteration in biology; Twist sells the scarce physical layer (high-fidelity DNA + workflow consumables) and can monetize trust/compliance as biosecurity permissioning tightens.

Twist is transitioning from “growth with losses” to “scaled platform with operating leverage.” The non-linear upside comes from moving up the stack: embedding into automated lab workflows (distribution), selling validated/regulated components (trust), and productizing biosecurity/provenance (permissioning). If management hits its FY2026 margin and breakeven path, investors can rationally underwrite 2031 as a durable picks-and-shovels platform for AI-accelerated biology, supporting a modest re-rate rather than a bubble multiple.

The key risks are (1) “good growth, bad multiple” if synthesis/NGS inputs commoditize, (2) permissioning/biosecurity compliance tightening and raising costs, and (3) concentration and single-point supply-chain dependency creating discontinuities that overwhelm operating leverage.

$39.00